Login

Switch On Your HIV Smarts.

Meth, Crack, Coke & Ecstasy: Effects on HIV Disease Progression

Meth, Crack, Coke & Ecstasy: Effects on HIV Disease Progression

, by Emily Newman

For the first time, a study investigates whether stimulants lead to poorer health outcomes for people with HIV—independent of antiretroviral use. Read More

Daily Antibiotic Protects Against Chlamydia, Gonorrhea and Syphilis

Daily Antibiotic Protects Against Chlamydia, Gonorrhea and Syphilis

, by Emily Newman

A small pilot study reveals that a common antibiotic can help men who have sex with men prevent three common STIs. Read More

Dolutegravir Shows Promise as Part of First-Line HIV Therapy

Dolutegravir Shows Promise as Part of First-Line HIV Therapy

, by Emily Newman

An integrase inhibitor fared well in a head-to-head comparison with a protease inhibitor regimen for people just starting ART. Find out why this is surprising and what it could mean for treatment naïve people with high viral loads. Read More

Supervisor Wiener: Reclassifying HIV Drugs as “Specialty” is Discriminatory

Supervisor Wiener: Reclassifying HIV Drugs as “Specialty” is Discriminatory

, by Emily Newman

Placing HIV and hepatitis C drugs on “specialty” tiers affects their access and affordability. Supervisor Scott Wiener called attention to this issue during a recent San Francisco hearing.
Read More

CROI 2015: Hepatitis C—Both the Good News and Bad

CROI 2015: Hepatitis C—Both the Good News and Bad

, by Liz Highleyman

Recent drug advances bring a cure for hepatitis C to many. But delayed treatment, liver disease, and drug costs all give cause for concern. Read More